- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
60 Degrees Pharmaceuticals is seeking MUMS designation from the FDA for its drug tafenoquine.
1 report, 1 independent
Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
60 Degrees Pharmaceuticals is seeking MUMS designation from the FDA for its drug tafenoquine.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- A study author is based in Johns Hopkins School of Medicine, and the research is connected to Baltimore, now involving the FDA for drug approval.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- Kazia Therapeutics Limited is seeking various regulatory designations from the FDA to support its drug development pipeline.
- The FDA recommended advancement for a new drug application submitted by a company.
- A product was launched in the U.S. market following FDA involvement.
Coverage
Newest first; wire copies grouped- GlobeNewswire60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025 Data from three independent clinical studies demonst